Entero Therapeutics, Inc. (ENTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entero Therapeutics, Inc. (ENTO) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-855.69K) by net assets ($89.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Entero Therapeutics, Inc. for the company's overall valuation and market capitalisation.
Entero Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Entero Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Entero Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entero Therapeutics, Inc. ranked by their cash flow conversion efficiency. Explore ENTO cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ:GDTC
|
-0.299x |
|
CoinSmart Financial Inc
NEO:SMRT
|
-0.279x |
|
Redivium Ltd
AU:RIL
|
2.594x |
|
Willamette Valley Vineyards Inc
NASDAQ:WVVI
|
0.029x |
|
Biovie Inc
NASDAQ:BIVI
|
-0.477x |
|
Cambium Bio Ltd
AU:CMB
|
-1.444x |
|
Akkhie Prakarn Public Company Limited
BK:AKP
|
0.036x |
|
Polar Capital Holdings plc
LSE:POLR
|
0.460x |
Annual Cash Flow Conversion Efficiency for Entero Therapeutics, Inc. (2013–2024)
The table below shows the annual cash flow conversion efficiency of Entero Therapeutics, Inc. from 2013 to 2024. View Entero Therapeutics, Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.80 Million | $-9.22 Million | -0.159x | +95.36% |
| 2023-12-31 | $3.60 Million | $-12.38 Million | -3.435x | +57.84% |
| 2022-12-31 | $2.74 Million | $-22.34 Million | -8.148x | -297.39% |
| 2021-12-31 | $-7.82 Million | $-32.29 Million | 4.128x | -2.86% |
| 2020-12-31 | $-2.64 Million | $-11.22 Million | 4.249x | +139914.20% |
| 2019-12-31 | $4.62 Million | $-14.03K | -0.003x | +99.87% |
| 2018-12-31 | $4.47 Million | $-10.87 Million | -2.430x | +7.63% |
| 2017-12-31 | $2.73 Million | $-7.18 Million | -2.630x | -86.35% |
| 2016-12-31 | $3.21 Million | $-4.53 Million | -1.411x | -122950.52% |
| 2015-12-31 | $-3.63 Million | $-4.17K | 0.001x | +400.15% |
| 2014-12-31 | $2.64 Million | $-1.01K | 0.000x | -100.04% |
| 2013-12-31 | $54.60 | $56.55 | 1.036x | -- |
About Entero Therapeutics, Inc.
Entero Therapeutics, Inc. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the resear… Read more